The first Japanese patent covering Histotype Px methods has been granted by the Japan Patent Office – marking our first patent in Japan and a significant step in strengthening our global IP portfolio. This is more than just a patent. It's a powerful validation of our innovation and a key enabler for an expansion in Asia and Japan, one of the world’s most advanced healthcare markets.

Another clinical validation will be presented at the 2025 ASCO Annual Meeting. This is the first European validation of Histotype Px® Colorectal in combination with circulating tumor DNA. The results not only reduce the risk of false negatives but also support more informed adjuvant chemotherapy decisions advancing us toward truly personalized colon cancer care.

DoMore Diagnostics has been granted its third U.S. patent by the U.S. Patent and Trademark Office (USPTO). This is the first grant in our second patent family, further strengthening the intellectual property foundation of our cutting-edge AI-powered digital biomarkers.

DoMore Diagnostics has been granted its first Asian patent by the Korean Intellectual Property Office. This marks a major step in expanding global protection for our AI-powered Histotype Px® biomarkers, supporting smarter cancer diagnostics and personalized care across Asia’s fast-growing healthcare markets.

DoMore Diagnostics has once again been awarded a NOK 16 million grant from the Research Council of Norway to advance our project “Novel AI-based biomarker to predict minimal residual disease and personalize treatment in colorectal cancer”.

DoMore Diagnostics and Aarhus University Hospital, ranked as Denmark's best hospital with high ambitions within the field of cancer, are proud to announce a clinical research collaboration.

Oslo Cancer Cluster Start-up Spotlight has published an article highlighting how our digital biomarker Histotype Px® Colorectal addresses the unmet needs for personalized treatment of colorectal cancer patients, the market potential and our recent achievements.

DoMore Diagnostics is pleased to announce the appointment of Dr. Lao Saal as our new consulting Medical Director. Lao’s expertise will play a key role in strengthening our clinical research as we prepare for the commercial launch and clinical implementation.

DoMore Diagnostics and PathAI enter into partnership making Histotype Px Colorectal available on AISight, the Image Management System from PathAI.

DoMore Diagnostics and Erasmus MC Cancer Institute, one of the world’s leading centers of cancer surgery and research, are proud to announce a clinical research collaboration.

DoMore Diagnostics is pleased to announce that a poster with clinical data on Histotype Px^® Colorectal in U.S. colon cancer patients was presented on November 3 at the Pathology Visions 2024 conference (Orlando, FL), organized by the U.S. Digital Pathology Association.